spacer
home > epc > autumn 2017 > compliance and modernisation
PUBLICATIONS
European Pharmaceutical Contractor

Compliance and Modernisation

The new ICH Good Clinical Practice (GCP) E6 Addendum Revision 2 (E6 R2) is the biggest amendment of the international guideline for over 20 years. The update was finalised in November 2016 and became effective in the EU on 14 June 2017, meaning organisations running clinical trials in this region should now be compliant with the new requirements.

However, in January 2017 – just two months after the new guideline was finalised – many were surprised when ICH announced that an even greater change is planned. The extra revision is being added to keep pace with the scale and complexity of clinical trials and to ensure appropriate use of technology.

Further Modernisation

ICH is proposing further updates to E6 R2 in what they are calling a ‘renovation’ – the scope of these further suggested changes will include clinical trial design, planning, management and conduct of clinical trials (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Laura Brown is Managing Director of a leading international training and quality assurance consultancy specialising in the pharmaceutical industry. She delivers a broad range of technical and management courses and consultancy for pharma, covering project management, ICH GCP R2, CAPA and clinical trial regulations. Laura is also Course Director, MSc Clinical Research, School of Pharmacy, Cardiff University, UK.
spacer
Dr Laura Brown
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement